Ionis Pharmaceuticals, Inc.
IONS
$54.99
-$1.03-1.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 267.95M | 246.09M | 203.33M | 156.72M | 452.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 267.95M | 246.09M | 203.33M | 156.72M | 452.05M |
| Cost of Revenue | 208.75M | 213.16M | 287.60M | 220.09M | 214.01M |
| Gross Profit | 59.20M | 32.94M | -84.27M | -63.37M | 238.04M |
| SG&A Expenses | 160.60M | 150.36M | 130.19M | 96.81M | 97.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 900.00K | -- | -- | -- | 1.10M |
| Total Operating Expenses | 370.24M | 363.52M | 417.79M | 316.90M | 312.23M |
| Operating Income | -102.29M | -117.42M | -214.46M | -160.18M | 139.82M |
| Income Before Tax | -113.38M | -92.31M | -227.92M | -128.39M | 123.53M |
| Income Tax Expenses | 1.26M | 218.00K | 1.48M | 213.00K | -20.00K |
| Earnings from Continuing Operations | -114.65M | -92.53M | -229.39M | -128.61M | 123.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.65M | -92.53M | -229.39M | -128.61M | 123.55M |
| EBIT | -102.29M | -117.42M | -214.46M | -160.18M | 139.82M |
| EBITDA | -98.16M | -113.46M | -210.56M | -157.31M | 142.68M |
| EPS Basic | -0.69 | -0.56 | -1.42 | -0.81 | 0.78 |
| Normalized Basic EPS | -0.39 | -0.44 | -0.82 | -0.62 | 0.56 |
| EPS Diluted | -0.69 | -0.56 | -1.42 | -0.81 | 0.70 |
| Normalized Diluted EPS | -0.39 | -0.44 | -0.82 | -0.62 | 0.49 |
| Average Basic Shares Outstanding | 165.42M | 164.87M | 162.00M | 159.77M | 159.14M |
| Average Diluted Shares Outstanding | 165.42M | 164.87M | 162.00M | 159.77M | 182.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |